TREATMENT PATTERNS AND OUTCOMES IN METASTATIC COLORECTAL CANCER (MCRC) PATIENTS TREATED IN A COMMUNITY ONCOLOGY SETTING

被引：0
|
作者：
Cartwright, T. H. [1 ]
Pan, I [2 ]
Wen, L. [3 ]
Wadlow, R. C. [4 ]
Rembert, D. [5 ]
Seal, B. [6 ]
机构：
[1] Mckesson Specialty Hlth, Ocala, FL USA
[2] Mckesson Specialty Hlth, Conroe, TX USA
[3] Bayer HealthCare Pharmaceut Inc, Pine Brook, NJ USA
[4] Mckesson Specialty Hlth, Fairfax, VA USA
[5] Mckesson Specialty Hlth, The Woodlands, TX USA
[6] Bayer HealthCare Pharmaceut Inc, White House Stn, NJ USA
来源：
VALUE IN HEALTH | 2014年 / 17卷 / 03期
关键词：
D O I：
10.1016/j.jval.2014.03.407
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PCN12
引用
收藏
页码：A69 / A70
页数：2
相关论文
共 50 条
  • [41] Predictors of attrition in the treatment of metastatic colorectal cancer (MCRC).
    Bahrabadi, Arvin
    Ruan, Jenny
    Gresham, Gillian
    Cheung, Winson Y.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [42] Treatment patterns and outcomes in patients with KRAS wild type (WT) metastatic colorectal cancer (mCRC) treated in first line with bevacizumab (B) or cetuximab (C) containing regimens.
    Houts, Arthur C.
    Ogale, Sarika
    Sommer, Nicolas
    Walker, Mark Stephen
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (04)
  • [43] Treatment of metastatic colorectal cancer (mCRC) according to age
    Ortega, Laura
    Torres Perez-Solero, Gabriela
    Arregui Valles, Marta
    Alva Bianchi, Manuel
    Aparicio Salcedo, Inmaculada
    Garcia Gonzalez, Gonzalo
    Gallego Gallego, Iria
    Munoz Martin, Andres J.
    Calvo Ferrandiz, Aitana
    Blanco-Codesido, Montserrat
    Martin, Miguel
    Garcia-Alfonso, Pilar
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (04)
  • [44] Safety of capecitabine plus bevacizumab in heavily treated patients with metastatic colorectal cancer (MCRC)
    Adamo, Vincenzo
    Festa, Vincenzo
    Restuccia, Eleonora
    Chiofalo, Giuseppe
    Maisano, Carmelo
    Picciotto, Maria
    Alafaci, Elisabetta
    Tortora, Giampaolo
    ANNALS OF ONCOLOGY, 2007, 18 : 16 - 17
  • [45] Sidedness and addition of chemotherapy associated with treatment outcomes of regorafenib for metastatic colorectal cancer (mCRC).
    Wu, Tsung-Che
    Liang, Yi-Hsin
    Chen, Kuo-Hsing
    Chuang, Chien Huai
    Shao, Yu Yun
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : 36 - 36
  • [46] Quality matters: Patterns of palliative interventions in metastatic colorectal cancer (mCRC) patients.
    Prince, Rebecca M.
    Liang, Shuyin
    Brar, Mantaj
    Ramkumar, Stephanie
    Scheer, Adena
    Wong, Rebecca
    Hallet, Julie I.
    Zimmermann, Camilla
    Easson, Alexandra Maria
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (31)
  • [47] Outcomes of long responders chemorefractory metastatic colorectal cancer (mCRC) patients (pts) treated with regorafenib: a single institution experience
    Sforza, V.
    Capasso, A.
    Nappi, A.
    Cardone, C.
    Martini, G.
    Ferrara, M. L.
    Napolitano, S.
    Vitiello, P.
    Vitale, P.
    Zanaletti, N.
    De Vita, F.
    Orditura, M.
    Troiani, T.
    Ciardiello, F.
    Martinelli, E.
    ANNALS OF ONCOLOGY, 2016, 27
  • [48] Quantitative urinary KRAS for treatment decisions in patients with metastatic colorectal cancer (mCRC)
    Melnikova, Vladislava
    Vibat, Cecile Rose T.
    Ning, Van
    Agafitei, Raluca Dana
    Hanna, Diana L.
    Hancock, Saege
    Erlander, Mark G.
    Lenz, Heinz-Josef
    Barzi, Afsaneh
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [49] Metastatic Colorectal Cancer in Hispanics: Treatment Outcomes in a Treated Population
    Shabihkhani, Maryam
    Steven, S. Yu
    Yang, Dongyun
    Lin, Sonia
    Hamilton, Ann S.
    Lenz, Heinz-Josef
    Barzi, Afsaneh
    CLINICAL COLORECTAL CANCER, 2016, 15 (04) : E221 - E227
  • [50] How to Identify the Right Patients for the Right Treatment in Metastatic Colorectal Cancer (mCRC)
    Saridaki, Zenia
    Asimakopoulou, Natalia
    Boukovinas, Ioannis
    Souglakos, John
    CURRENT COLORECTAL CANCER REPORTS, 2015, 11 (04) : 151 - 159
12345